归肾丸加减“异病同治” 治疗卵巢功能减退类疾病（肾虚精亏型）临床研究-中医妇科学专业论文.docxVIP

成都 成都中医药大学硕士学位论文 万方数据 万方数据 中文摘要 目的：在“异病同治”理论指导下，验证中药归肾丸加减治疗卵巢功能减退类 疾病的临床疗效，为本类疾病的治疗提供有效的方药。 方法：本研究在“异病同治”理论和“治未病”思想指导下，采用自身前后 对照试验的设计方法，将符合本类疾病肾虚精亏证证候诊断标准和相关纳入标准 的 115 例患者进行临床观察研究，以评价归肾丸加减对本类疾病的防治效果。 结果：（1）中医证候疗效：本研究总病例：愈显率为 47.83%，总有效率 89.66%； 卵巢储备功能下降：愈显率为 59.65%，总有效率 96.49%；卵巢早衰：愈显率为 23.08%，总有效率 69.23%；围绝经期综合征：愈显率为 46.88%，总有效率 96.88%。 且患者月经周期、量色质及潮热汗出、腰膝酸软、头晕耳鸣、心烦易怒、失眠多 梦、阴户干涩等证候积分治疗前后均有改善，差异均有统计学意义（P0.05）。 （2）理化指标疗效：本研究总病例：愈显率为 40.87%，总有效率 66.96%； 卵巢储备功能下降：愈显率为 70.18%，总有效率 89.47%。卵巢早衰：愈显率为 19.23%，总有效率 53.85%。围绝经期综合征：愈显率为 6.25%，总有效率 37.5%。 治疗后患者血清 E2 值均有所提高，差异有显著统计学意义（P0.01）；治疗 后 POF 和 DOR 患者的 FSH 水平有所降低，子宫体积有增加，差异均有统计学意义 （P0.05），但对 MPS 患者改善不明显（P0.05）；治疗后 DOR 和 MPS 的内膜厚度 有增加，差异有统计学意义（P0.05），但 POF 患者内膜厚度改善不明显（P0.05）； 治疗后患者卵巢体积改善不明显，差异无统计学意义（P0.05）。 结论：根据“异病同治”理论，归肾丸加减治疗卵巢功能减退类疾病如围绝经 期综合征、卵巢早衰、卵巢储备功能下降，能够较明显改善患者临床症状及相关 检测指标，值得临床进一步推广运用。 关键词：异病同治,归肾丸加减,卵巢功能减退类疾病 1 Abstract Objective: To evaluate the clinical curative effect of the addition and subtraction of Guishen Wan for the treatment of the diseases with hypoovarianism under the guidance of Treating different diseases with the same therapy theory. To provide an efficacious recipe for the treatment of these diseases. Methods: Adopting the contrast research method of before and after, we observe the TCM syndrome and detection indexes of 115 Patients meet the standards for diagnosis of the diseases with hypoovarianism (syndrome of kidney deficiency and essence insufficiency) under the guidance of Treating different diseases with the same therapy theory. Results: Effect of syndrome of TCM.The significant and cure rate of the total cases was 47.83%, total effective rate was 89.66%. The significant and cure rate of DOR Patients was 59.65%, total effective rate was 96.49%.The significant and cure rate of POF Patients was 23.08%, total effective rate was 69.23%.The significant and cure rate of MPS Patients was 46.88%, total effective rate was 96.88%. Treatment of before and after the TCM syndrome integral showed sign